← Companies
Immix Biopharma, Inc.
Data as of Nov 11, 2026
Lobbying
$480,000 in reported federal lobbying spend across 17 quarterly filings, most recently Nov 4, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.
Spend by issue
- Health Issues$220K12 filings
- Medical/Disease Research/Clinical Labs$210K3 filings
Latest filings, Oct 2026 onward
| Filed | Registrant and subject | Amount |
|---|---|---|
| Nov 4, 2026 | BROWNSTEIN HYATT FARBER SCHRECK, LLP for IMMIX BIOPHARMA INC. Pharmacy · Health Issues Issues surrounding biopharmaceutical research, development, and regulatory policy and standards.
Issues surrounding biopharmaceutical research, development, and regulatory policy and standards. | $0 |
| Oct 21, 2026 | YC CONSULTING, LLC for FIRST PRINCIPLES STRATEGIES LLC ON BEHALF OF IMMIX BIOPHARMA INC Health Issues Advancement of Congressional rare disease drug approval policies | $20,000 |
| Oct 21, 2026 | YC CONSULTING, LLC for FIRST PRINCIPLES STRATEGIES LLC ON BEHALF OF IMMIX BIOPHARMA INC Health Issues Rare Disease therapeutic policies | $0 |
| Oct 20, 2026 | CONTINENTAL STRATEGY, LLC for IMMIX BIOPHARMA INC. Medical/Disease Research/Clinical Labs FDA approval standards | $105,000 |
| Oct 20, 2026 | TARPLIN, DOWNS & YOUNG, LLC for IMMIX BIOPHARMA INC Health Issues innovation in rare disease treatment and pharmaceutical policy | $60,000 |
| Oct 20, 2026 | FIRST PRINCIPLES STRATEGIES, LLC for IMMIX BIOPHARMA INC. Health Issues Advancement of Congressional rare disease drug approval policies | $20,000 |